Results 311 to 320 of about 749,314 (382)

Identification of glucuronic acid as a biomarker of poor prognosis in acute myeloid leukemia based on plasma metabolomics. [PDF]

Clin Exp Med
Yang J, Wang Z, Wu K, Ruan J, Nie B, Zhou Q, Li L, Luo L, Zhang F, Shi M, Zeng Y.   +10 more
europepmc   +1 more source

Asciminib in Advanced-Line Treatment of Chronic Myeloid Leukemia. [PDF]

Eur J Haematol
Shacham-Abulafia A, Volcheck Y, Ellis M, Shapira S, Tavor S, Gourevitch A, Kreiniz N, Stanevski A, Raanani P, Koren-Michowitz M.   +9 more
europepmc   +1 more source

Mechanisms of enhancer‐driven oncogene activation

International Journal of Cancer, EarlyView.
Abstract An aggressive subtype of acute myeloid leukemia (AML) is caused by enhancer hijacking resulting in MECOM overexpression. Several chromosomal rearrangements can lead to this: the most common (inv(3)/t(3;3)) results in a hijacked GATA2 enhancer, and there are several atypical MECOM rearrangements involving enhancers from other hematopoietic ...
Joyce Vriend, Ruud Delwel, Dorien Pastoors   +2 more
wiley   +1 more source

Chronic myeloid leukemia in India

Indian Journal of Medical and Paediatric Oncology, 2013
openaire   +3 more sources

Targeting the Menin–KMT2A interaction in leukemia: Lessons learned and future directions

International Journal of Cancer, EarlyView.
Abstract Chromosomal rearrangements involving the Mixed Lineage Leukemia gene (MLL1, KMT2A) are defining a genetically distinct subset in about 10% of human acute leukemias. Translocations involving the KMT2A‐locus at chromosome 11q23 are resulting in the formation of a chimeric oncogene, where the N‐terminal part of KMT2A is fused to a variety of ...
Florian Perner, Jayant Y. Gadrey, Scott A. Armstrong, Michael W. M. Kühn   +3 more
wiley   +1 more source

Bone marrow immune cells and drug resistance in acute myeloid leukemia. [PDF]

Exp Biol Med (Maywood)
Zhang M, Yang Y, Liu J, Guo L, Guo Q, Liu W.   +5 more
europepmc   +1 more source

Enhancer‐dependent gene regulation in space, time, and malignancies

International Journal of Cancer, EarlyView.
Abstract Control of cell‐type‐specific gene activation requires the coordinated activity of distal regulatory elements, including enhancers, whose inputs must be temporally integrated. Dysregulation of this regulatory capacity, such as aberrant usage of enhancers, can result in malignant transformation of cells.
Belinda Blum, Victoria Dachtler, Angelika Feldmann   +2 more
wiley   +1 more source

Breakthroughs of CAR T-cell therapy in acute myeloid leukemia: updates from ASH 2024. [PDF]

Exp Hematol Oncol
Zhang H, Zhu HH.
europepmc   +1 more source

Therapeutic targeting of chromatin alterations in leukemia and solid tumors

International Journal of Cancer, EarlyView.
Abstract Alterations in chromatin conformation and post‐translational modification of histones have become increasingly recognized as critical drivers of cancer development, progression, and therapy resistance. Recent advances in drug development have led to the establishment of several highly selective small molecule inhibitors, several of which are ...
Florian Perner, Tobias Berg, Daniel Sasca, Sophie‐Luise Mersiowsky, Jayant Y. Gadrey, Johanna Thomas, Michael W. M. Kühn, Michael Lübbert   +7 more
wiley   +1 more source